Volume of grey brain matter significantly lower in people with Early Onset Psychosis
New research from the Institute of Psychiatry, Psychology & Neuroscience has found an association between a reduction in grey matter in the brain and Early Onset Psychosis (EOP).
The study, published in Molecular Psychiatry, is the largest ever brain imaging study in EOP and has provided unprecedented levels of detail about the illness. It shows that, in contrast to other mental health disorders, people with EOP have a reduced volume of grey matter across nearly all regions of their brain. Researchers hope that this detailed mapping could be used to assist in future diagnosis, as well as to track the effects of treatment in patients with EOP.
EOP occurs before the age of 18 during a critical period of development in the brain. Individuals diagnosed with the illness are likely to experience severe and long-lasting symptoms that respond less well to treatment. Despite this, research into EOP has been limited in sample size and statistical power.
The study represents an international effort, combining brain scans from Norway, Spain, Canada, Italy, Australia & UK, 482 individuals with EOP being compared to 469 healthy controls. An analysis of the data revealed that individuals with EOP had lower volumes of grey matter in almost all regions of the brain compared to the healthy controls, with a marked effect in the left median cingulate – an area of the brain associated with the formation and processing of emotions, learning and memory.
Dr Matthew Kempton, Reader in Neuroimaging Psychiatry at King’s IoPPN and the study’s senior author said, “Early Onset Psychosis can have a devastating impact on a person’s life and wellbeing, but our understanding of the illness is still sadly relatively limited. This study, the largest neuroimaging analysis of EOP to date, used newly developed technologies to combine scans from different sites to examine hundreds of thousands of data points measuring volume in the brain. We found that people with EOP experience a lower volume of grey matter in nearly all regions of their brains compared to people without the illness. This detailed map will hopefully provide the basis for future research, as it could help as a diagnostic tool, and even track the effectiveness of treatments.”
Further analysis of the data revealed that those individuals who developed EOP at a later age had lower volumes of grey matter in a number of small brain regions compared to those with an earlier age of onset.
Shuqing Si, the study’s first author from King’s IoPPN said, “Grey matter’s primary purpose is to process information in the brain and plays a significant role in day to day functions like memory, emotions and movement. This study used specially created software (ENIGMA-VBM) developed at King’s that can accurately map where there have been local increases and decreases in brain volume. It’s allowed our team to process significantly more data and has meant that our sample reflects brain scans from many parts of the world. The effectiveness of this software means we’re now investigating the brains of those with several other disorders.”
This study represents independent research, partly funded by the National Institute for Health and Care Research Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London.
Ends
For more information, please contact Patrick O’Brien (Media Manager)
Mapping gray and white matter volume abnormalities in early-onset psychosis - an ENIGMA multicenter voxel-based morphometry study (DOI 10.1038/s41380-023-02343-1 ) (Shuqing Si, Anbreen Bi, Zhaoying Yu, Cheryl See, Sinead Kelly, Sonia Ambrogi, Celso Arango, Inmaculada Baeza, Nerisa Banaj, Michael Berk, Josefina Castro-Fornieles, Benedicto Crespo-Facorro, Jacob J. Crouse, Covadonga M. Díaz-Caneja, Anne-Kathrin Fett, Adriana Fortea, Sophia Frangou, Benjamin I. Goldstein, Ian B. Hickie, Joost Janssen, Kody G. Kennedy, Lydia Krabbendam, Marinos Kyriakopoulos, Bradley J. MacIntosh, Pedro Morgado, Stener Nerland, Saül Pascual-Diaz, Maria Picó-Pérez, Fabrizio Piras, Bjørn Rishovd Rund, Elena de la Serna, Gianfranco Spalletta, Gisela Sugranyes, Chao Suo, Diana Tordesillas-Gutiérrez, Daniela Vecchio, Joaquim Radua, Philip McGuire, Sophia I. Thomopoulos, Neda Jahanshad, Paul M. Thompson, Claudia Barth, Ingrid Agartz, Anthony James, Matthew J Kempton) was published in Molecular Psychiatry.
JOURNAL
Molecular Psychiatry
METHOD OF RESEARCH
Observational study
SUBJECT OF RESEARCH
People
ARTICLE TITLE
Mapping gray and white matter volume abnormalities in early-onset psychosis - an ENIGMA multicenter voxel-based morphometry study
ARTICLE PUBLICATION DATE
10-Jan-2024
COI STATEMENT
PT and NJ were funded in part by Biogen, Inc., for research unrelated to this manuscript. GS has received speaker fees from Angelini Pharma for a topic unrelated to this manuscript. AF has received educational support from Otsuka-Lundbeck, Janssen Cilag and Rovi, unrelated to this manuscript. CA has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. CDC has received honoraria from Exeltis and Angelini unrelated to this manuscript. IB has received honoraria and travel support from Angelini, Otsuka-Lundbeck and Janssen. IA has received speaker's honorarium from Lundbeck. PM has received in the past 3 years grants, CME-related honoraria, or consulting fees from Angelini, AstraZeneca, Bial, Biogen, DGS-Portugal, FCT, FLAD, Janssen-Cilag, Gulbenkian Foundation, Lundbeck, Springer Healthcare, Tecnimede, Viatris and 2CA-Braga. IBH is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney, Australia. The BMC operates an early-intervention youth service at Camperdown under contract to headspace. IBH has previously led community-based and pharmaceutical industry-supported (Wyeth, Eli Lily, Servier, Pfizer, AstraZeneca, Janssen Cilag) projects focused on the identification and better management of anxiety and depression. He is the Chief Scientific Advisor to, and a 3.2% equity shareholder in, InnoWell Pty Ltd, which aims to transform mental health services through the use of innovative technologies.
No comments:
Post a Comment